ALK Gene Fusion Detection Probe

ALK Gene Fusion Detection Probe

Wuhan HealthCare manufactures innovative solutions for cancer and personalised medicine that answer questions related to the earlier diagnostic, prognosis and therapy selection. This has significantly changed the way patients are treated. Our product lines consist of DNA Fluorescence In Situ Hybridisation (FISH) probes for cancer clinical diagnosis, research and pharmacogenetics real-time PCR kits for drug sensitivity.
Human ALK gene fusion detection probe is specifically used for non-small cell lung cancer (NSCLC).

Product Advantages:

Speed: Tissue & Blood cell sample hybridisation time: 2 hours (Results available the same day).
Accuracy: Less non-specific background staining (dyeing). Increase difficult samples detection rate.
Reproducibility: Different laboratories test results are highly reproducible.

About ALK

ALK gene encodes a transmembrane receptor tyrosine kinase (RTK). The ALK-NPM1 fusion protein was first discovered in anaplastic large cell lymphoma (ALCL). It has been found to mutate, amplify or rearrange in other tumors, including neuroblastoma and non-small cell lung cancer. Chromosome rearrangement is the most common cause of ALK and other genes. Fusion, including ALK/EML4, ALK/RANBP2, ALK/ATIC, ALK/TFG, ALK/NPM1, ALK/SQSTM1, ALK/KIF5B, ALK/CLTC, ALK/TPM4 and ALK/MSN.

   Probe design

 

 

 

 

 

 

ALK gene break-apart probe uses an orange-red dye to label the 2p23.2 region (3′ end), and the green dye to label ALK gene 2p23.1-p23.2 region (5′ end). ALK gene break-apart probe detects all ALK gene rearrangements and avoids missed diagnosis by a single fusion gene (such as EML4-ALK).

Clinical significance

According to the 2013 edition of the Chinese consensus of diagnostic experts on anaplastic lymphoma kinase (ALK) positive non-small cell lung cancer, the positive rate of ALK gene is as high as 30%-42% in NSCLC patients with adenocarcinoma, young (< 60 years old), non-smoking and no mutation in EGFR, KRAS, HER2 or P53 genes. Pathological studies suggest that the positive rate of mucinous or solid adenocarcinomas with signet ring cells is higher than that of other types of lung adenocarcinomas.
In 2013, CFDA approved XALKORI (Crizotinib) for targeted therapy of advanced ALK-positive non-small cell lung cancer, and the necessary condition for XALKORI (Crizotinib) drug therapy is FISH for ALK-positive non-small cell lung cancer. Patients with positive ALK gene fusion are sensitive to XALKORI (Crizotinib).

                                                                                                                                                             ALK fusion [+]                  ALK fusion [-]

 

 View the full list of FISH reagents

 

References
• Rodig SJ, et al. (2009) Clin Cancer Res 15: 5216-23.
• Sasaki T, et al. (2010) Eur J Cancer 46: 1773-80.
• Von Laffert M, et al. (2013) Lung Cancer 81: 200-6.

ALK Gene Fusion Detection Probe

Contact us